Opinion · 25 Jun 2026
Conference abstractPublished 28 Nov 2016
nanoZER-Novel treatment for cancer
Universiti Putra Malaysia, Malaysia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Cancer nanotherapy is progressing rapidly with the introduction of many innovative drug delivery systems to replace conventional therapy. Zerumbone, a natural dietary lipophilic compound with low water solubility (1.296 mg/L at 25Ã?°C) was used in this investigation. The zerumbone was loaded into nanostrucÃ?¬tured lipid carriers using a hot, high-pressure homogenization technique. The physicochemical properties of the zerumbone-loaded nanostructured lipid carriers (ZER-NLC) were determined. The ZER-NLC particles had an average size of 52.68Ã?±0.1 nm and a polydispersity index of 0.29Ã?±0.004 Ã?¼m. Transmission electron microscopy showed that the particles were spherical in shape. The zeta potential of the ZER-NLC was âÂ?Â?25.03Ã?±1.24 mV, entrapment efficiency was 99.03%, and drug loading was 7.92%. In vitro drug release of zerumbone from ZER-NLC was 46.7%, and for a pure zerumbone dispersion was 90.5% over 48 hours, following a zero equation. Using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay in human T-cell acute lymphoblastic leukemia (Jurkat) cells, the half maximal inhibitory concentration (IC50) of ZER-NLC was 5.64Ã?±0.38 Ã?¼g/mL, and for free zerumbone was 5.39Ã?±0.43 Ã?¼g/mL after 72 hours of treatment. This study strongly suggests that ZER-NLC have potential as a sustained-release drug carrier system for the treatment of leukemia. Although the antitumor activity of zerumbone (ZER) has been reported, there has been no information available on the effect of ZER-loaded nanostructured lipid carrier (NLC) (nanoZER) on murine leukemia cell. The in vitro and in vivo effects of nanoZER on murine leukemia induced with WEHI-3B cells were investigated. The results from 3-[4,5-dimethylthiazol-2-yl]-2,5-iphenyltetrazolium bromide, Hoechst 33342, Annexin V, cell cycle, and caspase activity assays showed that the growth of leukemia cells in vitro was inhibited by nanoZER. In addition, outcomes of histopaÃ?¬thology, transmission electron microscopy, and Tdt-mediated dUTP nick-end labeling analyses revealed that the number of leukemia cells in the spleen of BALB/c leukemia mice significantly decreased after 4 weeks of oral treatment with various doses of nanoZER. Western blotting and reverse-transcription quantitative polymerase chain reaction assays confirmed the anti-leukemia effects of nanoZER. In conclusion, nanoZER was shown to induce a mitochondrial-dependent apoptotic pathway in murine leukemia. Loading of ZER in NLC did not compromise the anti-cancer effect of the compound, suggesting nanoZER as a promising and effective delivery system for treatment of cancer.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Translational Medicine.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalTranslational Medicine
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Heshu S Rahman”
- BylineArticles whose byline prints “Hemn H Othman”
- BylineArticles whose byline prints “Rasedee A”
